



Acucela Inc.  
454 North 34th Street  
Seattle, WA 98103  
Tel: 206 812.1530  
Fax: 206 545.3885

---

July 12, 2006

## **Acucela Presents at ARVO Summer Conference on Macular Degeneration**

Acucela Inc., a biotechnology company focusing on discovering and developing new treatments for blinding eye diseases, presented at the Association for Research in Vision Ophthalmology (ARVO) summer conference, which focused on prevention of age related macular degeneration. Two posters were submitted, the first entitled "Electroretinographic Changes in ELOVL4 TG2 Mice After Repeated Administration of ACU-3223". This resulted in the first time a compound has shown efficacy in the ELOVL4 mouse model, a transgenic mouse model for Stargardt's-like macular degeneration. The initial results showed both preservation of photoreceptors as well as reduction of A2E, a toxic byproduct of the visual cycle.

The second poster is called "Identification of Neuroprotective Compounds Against Light-Induced Photoreceptor Death in Primary Bovine Retinal Cell Culture". Acucela has developed a proprietary cell-based screening system which can be used for identifying compounds for treating certain ophthalmic diseases, as well as identifying compounds which may be toxic to ocular cells.

### **Press Contact**

Acucela Inc.

Jeff Chen (U.S.)  
206-812-1530  
jeffchen@acucela.com

Kenzo Ogiwara (Japan)  
050-5534-8201  
kogiwara@acucela.com